J. Bertino

发表

Comparison of midazolam and simvastatin as cytochrome P450 3A probes

D. Kazierad, E. Chung, A. Nafziger, 2006, Clinical pharmacology and therapeutics.

A. Kashuba, J. Bertino, Joseph S. Bertino, 2005 .

Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Joseph D. Ma, A. Nafziger, J. Bertino, 2009, British journal of clinical pharmacology.

Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered

A. Nafziger, J. Bertino, Lois S. Lee, 2005, Clinical pharmacology and therapeutics.

Effects of Oral Vitamin K on S‐ and R‐Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe

A. Rettie, A. Gaedigk, A. Nafziger, 2001, Journal of clinical pharmacology.

Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam

A. Nafziger, J. Bertino, Maylee Chen, 2006, Drug Metabolism and Disposition.

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.

A. Nafziger, J. Bertino, R. Kulawy, 2001, Pharmacogenetics.

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

D. Greenblatt, E. Choo, G. Wilkinson, 2002, Journal of clinical pharmacology.

Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

E. Choo, G. Wilkinson, A. Kashuba, 2002, Journal of clinical pharmacology.

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

S. Gotzkowsky, A. Kashuba, Ya-Chi Chen, 2006, British journal of clinical pharmacology.

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

A. Gaedigk, J. Kirchheiner, A. Kashuba, 2006, European Journal of Clinical Pharmacology.

Effect of a Triphasic Oral Contraceptive on Drug‐Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail

E. Sellers, G. Kearns, A. Gaedigk, 2005, Journal of clinical pharmacology.

Limited Sampling Strategy of S‐Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S‐Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers

A. Gaedigk, A. Kashuba, A. Nafziger, 2004, Journal of clinical pharmacology.

Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”

E. Sellers, G. Kearns, A. Gaedigk, 2003, Clinical pharmacology and therapeutics.

Comparative Pharmacokinetics and Pharmacodynamic Target Attainment of Ertapenem in Normal-Weight, Obese, and Extremely Obese Adults

G. Drusano, A. Nafziger, J. Bertino, 2006, Antimicrobial Agents and Chemotherapy.

Desirudin Dosing and Monitoring in Moderate Renal Impairment

A. Nafziger, J. Bertino, 2010, Journal of clinical pharmacology.

Absence of Tobramycin Pharmacokinetic and Creatinine Clearance Variation During the Menstrual Cycle: Implied Absence of Variation in Glomerular Filtration Rate

A. Nafziger, J. Bertino, M. Schwartzman, 1989, Journal of clinical pharmacology.

Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions

O. Naderer, A. Nafziger, J. Bertino, 1997, Antimicrobial agents and chemotherapy.

Aminoglycoside dosing weight correction factors for patients of various body sizes

A. Traynor, A. Nafziger, J. Bertino, 1995, Antimicrobial agents and chemotherapy.

A. Nafziger, J. Bertino, 2004, European Journal of Clinical Pharmacology.

Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism.

A. Nafziger, J. Bertino, T. Jennings, 1993, The Journal of laboratory and clinical medicine.

Quantitation of three‐month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N‐acetyltransferase‐2, and xanthine oxidase activity determined with caffeine phenotyping

G. Kearns, J. Leeder, A. Kashuba, 1998, Clinical pharmacology and therapeutics.

Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo

E. Schuetz, G. Kearns, J. Leeder, 2003, Clinical pharmacology and therapeutics.

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes

Joseph D. Ma, A. Nafziger, J. Bertino, 2010, Clinical pharmacokinetics.

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

G. Kearns, R. Ellis, A. Gaedigk, 1999, Clinical pharmacology and therapeutics.

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

G. Kearns, A. Gaedigk, J. Leeder, 1998, Pharmacogenetics.

Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.

G. Kearns, A. Gaedigk, J. Leeder, 1999, Pharmacogenetics.

Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults

A. Gaedigk, Joseph D. Ma, A. Nafziger, 2006, Antimicrobial Agents and Chemotherapy.

The clopidogrel conundrum

J. Bertino, 2014, Journal of clinical pharmacology.

Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?

J. Murray, A. Nafziger, J. Bertino, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Dose‐Ranging Study of Gentamicin Pharmacokinetics: Implications for Extended Interval Aminoglycoside Therapy

D. Mcnamara, A. Nafziger, J. Bertino, 2001, Journal of clinical pharmacology.

Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers

A. Nafziger, J. Bertino, 1996, Antimicrobial agents and chemotherapy.

Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses

A. Nafziger, J. Bertino, M. Wong, 1994, Antimicrobial Agents and Chemotherapy.

Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.

A. Nafziger, J. Bertino, A. Kashuba, 1999, The Journal of clinical psychiatry.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction

L. Lewis, A. Kashuba, Joseph D. Ma, 2016, Therapeutic drug monitoring.

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

E. Sellers, A. Gaedigk, A. Nafziger, 2002, Clinical pharmacology and therapeutics.

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing

A. Nafziger, J. Bertino, D. Demczar, 1997, Antimicrobial agents and chemotherapy.

Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.

A. Nafziger, J. Bertino, M. Karl, 2000, Archives of internal medicine.

Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults

D. Yim, E. Capparelli, O. Yin, 2018, Therapeutic drug monitoring.

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

A. Nafziger, J. Bertino, J. F. Rogers, 2002, The American journal of medicine.

Application of Bayes Theorem to Aminoglycoside‐Associated Nephrotoxicity: Comparison of Extended‐Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple‐Daily Dosing

A. Nafziger, J. Bertino, T. Erb, 2004, Journal of clinical pharmacology.

in single and multiple doses . pharmacokinetics of fleroxacin administered Effect of a fat-and calcium-rich breakfast on

A. Nafziger, J. Bertino, M. Wong, 2022 .

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

A. Nafziger, J. Bertino, D. Streetman, 2000, Pharmacogenetics.

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail”

Andrea Gaedigk, G. Kearns, A. Gaedigk, 2000, Clinical pharmacology and therapeutics.

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics

J. Bertino, J. Bertino, M. Schwartzman, 1986, Clinical pharmacology and therapeutics.

Pharmacological Differences between Men and Women

M. J. Berg, A. Nafziger, J. Bertino, 2007 .

Lack of Effects of Diltiazem on Digoxin Pharmacokinetics

John J. May, J. Bertino, Teresa R. Beltrami, 1985, Journal of clinical pharmacology.

Lack of effect of atenolol and nadolol on the metabolism of theophylline.

A. Nafziger, J. Bertino, J. Pieper, 1990, British journal of clinical pharmacology.

Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors

M. Desai, R. Goodman, G. Mckhann, 2006, Clinical Cancer Research.

The Absolute Bioavailability of Oral Melatonin

J S Bertino, D. Blask, D E Blask, 2000, Journal of clinical pharmacology.

Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

C. Destache, A. Nafziger, J. Bertino, 2001, Pharmacotherapy.

Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents

A. Nafziger, J. Bertino, S. Kohlhepp, 1996, Antimicrobial agents and chemotherapy.

Flumazenil reduces midazolam‐induced cognitive impairment without altering pharmacokinetics

A. Nafziger, J. Bertino, M. Rocci, 2002, Clinical pharmacology and therapeutics.

Sex differences in CYP3A activity using intravenous and oral midazolam

G. Drusano, A. Nafziger, J. Bertino, 2006, Clinical pharmacology and therapeutics.

Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers

Joseph D. Ma, A. Nafziger, J. Bertino, 2004, Journal of clinical pharmacology.

Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia

J. V. Etzel, A. Nafziger, J. Bertino, 1992, Antimicrobial Agents and Chemotherapy.

Variation inthePharmacokinetics ofGentamicin andTobramycin in Patients withPleural Effusions andHypoalbuminemia

A. Nafziger, J. Bertino, 1992 .

Utility and Application of Urine Drug Testing in Chronic Pain Management With Opioids

A. Nafziger, J. Bertino, 2009, The Clinical journal of pain.

Measured versus Estimated Creatinine Clearance in Patients with Low Serum Creatinine Values

J. Bertino, 1993, The Annals of pharmacotherapy.

Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients

A. Nafziger, J. Bertino, M. Pai, 2011, Antimicrobial Agents and Chemotherapy.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping

G. Kearns, J. Leeder, A. Kashuba, 1998, Clinical pharmacology and therapeutics.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants

Victoria M. Pratt, Anick Bérard, Andrea Gaedigk, 2010, Front. Pharmacol..

Validating Phenotyping Cocktails: More Work Needs to Be Done

Joseph D. Ma, A. Nafziger, J. Bertino, 2012, Journal of clinical pharmacology.

Outcomes of Weight‐Based Heparin Dosing Based on Literature Guidelines and Institution Individualization

P. Dietz, J. Bertino, J. Bertino, 2000, Pharmacotherapy.

Lack of Weight‐Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping

E. Sellers, A. Gaedigk, A. Nafziger, 2004, Journal of clinical pharmacology.

Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1‐Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity

A. Nafziger, J. Bertino, Lois S Lee, 2006, Journal of clinical pharmacology.

Over‐the‐Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration‐Approved Oral Progesterone Product

A. Nafziger, J. Bertino, R. Kulawy, 2005, Journal of clinical pharmacology.

Probe Cocktail Studies

A. Nafziger, J. Bertino, 2011 .

Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults

E. Sellers, A. Nafziger, J. Bertino, 2006, Journal of clinical pharmacology.

DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM

G. Rhodes, Joseph D. Ma, A. Nafziger, 2006, Drug Metabolism and Disposition.

Evaluation of Four Once‐Daily Aminoglycoside Dosing Nomograms

J. Bertino, J. Bertino, A. W. Wallace, 2002, Pharmacotherapy.

Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam

A. Kashuba, A. Nafziger, J. Bertino, 1998, Clinical pharmacology and therapeutics.

Opportunistic Journals in the Clinical Pharmacology Space

D. Greenblatt, J. Bertino, 2018, Journal of clinical pharmacology.

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

H. Greenberg, E. Capparelli, Joseph D. Ma, 2018, Journal of clinical pharmacology.

American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process

H. Greenberg, J. Bertino, Howard E Greenberg, 2007, Journal of clinical pharmacology.

An evaluation of the atkins' diet.

Bernard V. Miller, A. Nafziger, J. Bertino, 2003, Metabolic syndrome and related disorders.

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

T. Fullerton, P. Snyder, N. Lawendy, 2009, International journal of clinical pharmacology and therapeutics.

Endogenous 4β-Hydroxycholesterol-to-Cholesterol Ratio Is Not a Validated Biomarker for the Assessment of CYP3A Activity

Joseph D. Ma, A. Nafziger, J. Bertino, 2013, Drug Metabolism and Disposition.

Inhibition of Theophylline Elimination by Diltiazem Therapy

John J. May, A. Nafziger, J. Bertino, 1987, Journal of clinical pharmacology.

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults

E. Capparelli, A. Kashuba, Joseph D. Ma, 2021, European Journal of Clinical Pharmacology.

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Ronald N. Jones, G. Drusano, F. Sörgel, 2010, Diagnostic microbiology and infectious disease.

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

J. Bertino, M. Rocci, J. F. Rogers, 2003, Clinical pharmacology and therapeutics.

Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.

Joseph D. Ma, A. Nafziger, J. Bertino, 2012, Drug metabolism letters.

Distribution of Orthopaedic Surgeons, Lawyers, and Malpractice Claims in New York

M. Ries, A. Nafziger, J. Bertino, 1997, Clinical orthopaedics and related research.

The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe

G. Rhodes, Joseph D. Ma, A. Nafziger, 2006, Journal of clinical pharmacology.

Prediction of midazolam (MDZ) clearance (CL) using minimized sampling (MS) of 1-OHM and 1-OHM/MDZ in healthy subjects (HS)

E. Choo, G. Wilkinson, A. Kashuba, 2001 .

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

A. Nafziger, J. Bertino, J. Bertino, 1993, The Journal of infectious diseases.

The Effects of a Beta‐2 Selective Adrenergic Agonist and a Beta‐Nonselective Antagonist on Theophylline Clearance

E. Middleton, T. Lombardi, R. Slaughter, 1987, Journal of clinical pharmacology.

Lack of effect of atenolol on the pharmacokinetics of theophylline.

E. Ludwig, E. Middleton, R. Slaughter, 1988, British journal of clinical pharmacology.

Quantitative assessment of hepatic blood flow using intravenous indocyanine green

Joseph D. Ma, A. Nafziger, J. Bertino, 2008, European Journal of Clinical Pharmacology.

Opportunistic Journals in the Clinical Pharmacology Space

D. Greenblatt, J. Bertino, J. Bertino, 2018, Clinical pharmacology in drug development.